#### Check for updates

#### **OPEN ACCESS**

EDITED BY Lei Huang, University of Massachusetts Medical School, United States

REVIEWED BY

German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Germany Zhouxuan Li, University of Texas MD Anderson Cancer Center, United States Yujia Ji, Stony Brook University, United States

\*CORRESPONDENCE Guosong Jiang Ø jiangguosong@kmmu.edu.cn

RECEIVED 18 April 2025 ACCEPTED 23 June 2025 PUBLISHED 10 July 2025 CORRECTED 11 July 2025

#### CITATION

Wang X, Feng C, Zhang B and Jiang G (2025) Association between triglyceride-glucose and triglyceride-glucose related indices with allcause mortality in depression participants: a cohort study from NHANES. *Front. Psychiatry* 16:1614421. doi: 10.3389/fpsyt.2025.1614421

#### COPYRIGHT

© 2025 Wang, Feng, Zhang and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

## Association between triglyceride-glucose and triglyceride-glucose related indices with all-cause mortality in depression participants: a cohort study from NHANES

## Xinxing Wang<sup>1</sup>, Chengya Feng<sup>2</sup>, Bo Zhang<sup>1</sup> and Guosong Jiang<sup>3</sup>\*

<sup>1</sup>Clinical Laboratory, Chengdu BOE Hospital, Chengdu, Sichuan, China, <sup>2</sup>Laboratory Department, Deyang Jingyang Maternal and Child Health Hospital, Deyang, Sichuan, China, <sup>3</sup>Department of Pulmonary and Critical Care Medicine, The First People's Hospital of Zhaotong City & The Zhaotong Affiliated Hospital of Kunming Medical University, Zhaotong, Yunnan, China

**Background:** While the triglyceride-glucose (TyG) index and related indices have been recognized as markers of insulin resistance and cardiometabolic disorders, few studies have examined their association with all-cause mortality in individuals with depression. This study aimed to investigate the relationship between the TyG index, its related indices, and all-cause mortality among patients with depression in the United States.

**Methods:** A total of 3,179 patients with depression were identified from the National Health and Nutrition Examination Survey (NHANES, 2005–2018). Participants were categorized into tertiles (T1, T2, T3) based on the TyG index and its derived indices: TyG combined with body mass index (TyG-BMI), waist circumference (TyG-WC), and waist-to-height ratio (TyG-WHtR). Cox regression analysis and Kaplan–Meier curve analysis were used to explore the relationship between the independent variable TyG and its derived indicators and the dependent variable all-cause mortality.Curve fitting and threshold effect analyses were performed to evaluate potential nonlinear or dose-response relationships. Subgroup and sensitivity analyses were conducted to validate the robustness of the results.

**Results:** Over a 13-year follow-up period, both the lowest and highest tertiles of the TyG index and its related indices were associated with significantly increased risks of all-cause mortality compared to the middle tertile. Restricted cubic spline analysis revealed U-shaped nonlinear relationships between these indices and all-cause mortality, with distinct threshold effects. Among the indices, TyG-BMI and TyG-WC demonstrated the strongest associations, though similar trends were observed for the other TyG-related indices.

**Conclusion:** This study identified nonlinear associations between the TyG index and its related indices (TyG-BMI, TyG-WC, TyG-WHtR) and all-cause mortality in patients with depression, with clear threshold effects. These findings highlight the potential utility of stratified risk assessment and targeted interventions based on these thresholds.

#### KEYWORDS

all-cause mortality, depression, triglyceride glucose, triglyceride glucose body mass index, triglyceride glucose-waist circumference, triglyceride glucose-waist height ratio, National Health and Nutrition Examination Survey (NHANES)

## **1** Introduction

Depression is a globally prevalent psychiatric disorder that significantly impairs quality of life and social functioning. It is associated with elevated all-cause mortality, with individuals experiencing depression having a 2.1-fold higher mortality rate compared to the general population (1, 2). Moreover, depression markedly increases mortality risk through its pathophysiological links to life-threatening comorbidities, such as cardiovascular and cerebrovascular diseases (3–9). Mechanistically, this increased mortality burden may be mediated by insulin resistance (IR), a core feature of metabolic syndrome (MetS) that contributes to multiorgan dysfunction (10). These findings underscore the importance of investigating IR-related biomarkers in the pathophysiology and clinical management of depression.

The triglyceride-glucose (TyG) index has been validated as a practical and cost-effective surrogate marker for IR, demonstrating significant clinical utility in risk stratification and prognostic evaluation across a range of disease states (11, 12). Recent population-based studies have identified strong associations between elevated TyG index levels and all-cause mortality in individuals with cardiometabolic disorders, including cardiovascular disease (11) and diabetes mellitus (9). As a sensitive indicator of systemic metabolic homeostasis, the TyG index has growing relevance in populations where metabolic dysregulation is a major contributor to excess mortality, such as those with depression (12). Further refinement of the TyG index has led to the development of triglyceride-glucose obesity indices, including the TyG-body mass index (TyG-BMI), TyG-waist circumference (TyG-WC), and TyGwaist-to-height ratio (TyG-WHtR). These indices enhance metabolic risk prediction by integrating assessments of IR (via glucose-lipid imbalance), visceral adiposity (reflected by BMI or WC, which indicate adipose tissue dysfunction and increased free fatty acid release), and ectopic lipid deposition (e.g., hepatic steatosis). This multidimensional approach provides a more comprehensive picture of metabolic dysfunction and has demonstrated superior predictive value compared to individual biomarkers (13-16). Based on this evidence, we hypothesize that the TyG index and its related indices are associated with all-cause mortality in individuals with depression. To explore this hypothesis, we conducted a study using data from the National Health and Nutrition Examination Survey (NHANES) 2005–2018 to examine the associations between TyG indices and all-cause mortality among patients with depression. The findings aim to provide new insights for the prevention and management of depression and to support an integrated care model addressing metabolic-psychiatric multimorbidity.

## 2 Methods

## 2.1 Study design

Analytical datasets were derived from publicly available cycles of the National Health and Nutrition Examination Survey (NHANES) conducted between 2005 and 2018. NHANES utilizes a stratified, multistage probability sampling design to systematically collect nutritional and health data from a nationally representative sample of non-institutionalized U.S. civilians. Ethical approval for all NHANES protocols was granted by the National Center for Health Statistics (NCHS) Ethics Review Board in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to data collection (17). Detailed documentation regarding NHANES methodology, including sampling procedures and ethical oversight, is available through the Centers for Disease Control and Prevention (CDC) website (https://www.cdc.gov/nchs/nhanes/index.htm).

### 2.2 Study population

As illustrated in Figure 1, a total of 67,365 NHANES participants were initially screened. After applying exclusion criteria, 3,179 participants were included in the final analysis. Exclusions were made as follows: 1) individuals aged <20 years and with a Patient Health Questionnaire-9 (PHQ-9) total score  $\leq 5$  (18), N = 58345; 2) participants with incomplete data on TyG indices and all-cause mortality, N = 5152; 3) participants missing covariate data (age, marital status, poverty-income ratio (PIR), educational level, smoking status, or hyperlipidemia), N = 689.



Flow chart of the study population inclusion. Flow chart of participants selection. NHANES, National Health and Nutrition Examination Survey; TyG, triglyceride-glucose; TyG-BMI, TyG with body mass index; TyG-WC, TyG with waist circumference; TyG-WHtR, TyG with waist-to-height ratio; PIR, poverty-income ratio.

## 2.3 TyG and TyG-related indices

Venous blood samples were obtained from fasting participants by trained medical professionals following standardized protocols. These samples were analyzed in a central laboratory to measure serum TG and fasting plasma glucose (FPG) levels using an enzymatic colorimetric method. The TyG index was calculated using the following formula: TyG = ln (TG (mg/dL) × FPG (mg/ dL)/2). TG concentrations were measured using the Roche Modular P and Cobas 6000 systems, while FPG levels were assessed using the hexokinase method on a Roche/Hitachi Cobas C 501 analyzer (19).

Participants' height and weight were measured three times using a stadiometer and weighing scale, respectively, with participants barefoot and wearing minimal clothing. WC was also measured three times by trained staff using a flexible tape positioned at the level of the navel. The mean of the three measurements was used for each parameter in subsequent analyses.

BMI was calculated as weight (kg) divided by height in meters squared (m<sup>2</sup>). The waist-to-height ratio (WHtR) was calculated as WC (cm) divided by height (cm). To enhance the predictive value of

the TyG index, it was combined with BMI, WC, and WHtR to generate the composite indices: TyG-BMI, TyG-WC, and TyG-WHtR. These were calculated using the following formulas (20):

TyG-BMI = TyG 
$$\times$$
 BMI  
TyG-WC = TyG  $\times$  WC  
TyG-WHtR = TyG  $\times$  WHtR

Participants were stratified into tertiles based on each TyGrelated index, with the second tertile serving as the reference group for all subsequent analyses.

## 2.4 Outcomes and follow-up

The National Death Index is updated every 4 years, with the most recent follow-up data available through December 31, 2019. Accordingly, the follow-up period for each participant was calculated from the date of their initial examination at the Mobile Examination Center (MEC) until either the occurrence of death or the end of the study period (December 31, 2019), whichever came first. Mortality status was determined through probabilistic linkage of the NHANES cohort with the Centers for Disease Control and Prevention's National Death Index as of December 31, 2019. All-cause mortality was defined as death from any cause, regardless of etiology. Cause-specific mortality categories were classified according to the International Classification of Diseases, Tenth Revision (ICD-10), and included the following: cardiovascular disorders (codes 054-068), malignant neoplasms (019-043), chronic lower respiratory tract diseases (082-086), unintentional traumatic injuries (112-123), cerebrovascular pathologies (070), Alzheimer's dementia (052), diabetes mellitus (046), influenzapneumonia complex (076-078), nephropathies including nephritic syndrome and renal degeneration (097-101), along with residual miscellaneous causes (21, 22).

## 2.5 Ascertainment of depression

The Patient Health Questionnaire-9 (PHQ-9) is a validated 9item screening tool used to assess the severity of depressive symptoms experienced over the preceding 2 weeks (18, 23). Numerous studies have confirmed its reliability and validity as a diagnostic instrument for depression (23, 24), consistent with the criteria for major depressive disorder as outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Each of the nine items is scored from 0 to 3, based on the participant's response: "not at all," "several days," "more than half the days," or "nearly every day." The total PHQ-9 score ranges from 0 to 27, with scores of 0–4 indicating no depression, and scores  $\geq 5$ suggesting the presence of depressive symptoms. Depression severity was further classified as follows: mild (5-9), moderate (10-14), and severe ( $\geq$ 15). These categories have been used in previous studies to investigate associations between depression severity and other clinical or demographic variables (25, 26).

## 2.6 Assessment of covariates

Demographic variables, including age, sex, race/ethnicity, educational level, marital status, and family income, were collected using a computer-assisted personal interview system. Information on lifestyle factors and comorbidities, including smoking (27), alcohol consumption (28), and hyperlipidemia, was gathered. Hyperlipidemia was defined as meeting any of the following criteria: use of lipidlowering medication, triglycerides ≥150 mg/dL, total cholesterol ≥200 mg/dL, LDL cholesterol ≥130 mg/dL, or HDL cholesterol <40 mg/dL (29). Physical examinations, including measurements of waist circumference, weight, and height, were performed following standardized protocols at mobile examination centers.

### 2.7 Statistical analysis

All statistical analyses were conducted using R version 4.2.2 (http://www.R-project.org, R Foundation) and Free Statistics

version 2.2.0. FreeStatistics is a software package that provides intuitive interfaces for common statistical analyses and data visualization. It uses R as the underlying statistical engine, with a graphical user interface (GUI) developed in Python. A P-value of less than 0.05 was considered statistically significant.

The normality of continuous variables was initially assessed using histogram analysis. For variables with a normal distribution, parametric tests were applied, and comparisons among multiple groups were conducted using analysis of variance (ANOVA), with results reported as mean ± standard deviation. For non-normally distributed variables, non-parametric tests were used, specifically the Kruskal–Wallis test for comparisons across multiple groups, with results expressed as median and interquartile range (IQR). Categorical variables were analyzed using non-parametric methods, primarily the Chi-square test, and were reported as percentages within frequency categories.

Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between TyG, TyG-BMI, TyG-WC, TyG-WHtR, and all-cause mortality. Trends across tertiles were assessed by modeling tertile levels as ordinal variables and evaluating the corresponding P-values. The proportional hazards assumption was tested using the Schoenfeld residuals test, with no violations detected. All models were adjusted for age, sex, race/ ethnicity, marital status, education level, poverty-income ratio (PIR), smoking status, alcohol consumption, and hyperlipidemia. To address multicollinearity, variance inflation factors (VIFs) were calculated for all covariates, and only variables with VIF < 5 were retained in the models. Missing covariates were directly removed as they accounted for less than 5% of the dataset. Restricted cubic splines were used to visualize the dose-response relationships between TyG indices and all-cause mortality. The number of knots (three) was selected based on minimizing the Akaike Information Criterion (AIC) to balance model fit and the risk of overfitting (30). In cases of nonlinear associations, potential threshold inflection points were identified, and two-piece Cox proportional hazards models were constructed to examine the relationship on either side of the threshold. Kaplan-Meier survival curves were plotted to illustrate differences in survival rates across tertiles of TyG, TyG-BMI, TyG-WC, and TyG-WHtR among participants with depression.

To further explore the associations between TyG,TyG-related indices and all-cause mortality, subgroup analyses were conducted by stratifying participants according to age, sex, and hyperlipidemia status. In addition, given the hormonal fluctuations associated with menopause and their potential impact on metabolic outcomes, participants were categorized into premenopausal (<45 years), perimenopausal (45–55 years), and postmenopausal (>55 years) groups for further stratified analysis in fully adjusted models (31, 32). Sensitivity analyses were performed to test the robustness of the results by: 1) excluding the lowest 0.5% and highest 0.5% of values to reduce the influence of outliers, and 2) excluding participants with diabetes to assess whether the associations between TyG indices and all-cause mortality remained consistent with the primary findings.

## **3 Results**

## 3.1 Baseline characteristics of participants

A total of 3,179 participants with depression were included in the analysis (mean age = 48.8 years, SD = 17.1), of whom 1,941 (61.1%) were female. During a mean follow-up period of 7.16 years, 360 deaths (11.3%) from all causes were recorded. Table 1 presents the baseline demographic and clinical characteristics of participants stratified by TyG index tertiles. Participants in the higher TyG tertiles were more likely to be older, non-Hispanic White, consume alcohol more frequently, and have a significantly higher prevalence of hyperlipidemia (P < 0.01).

Variables	Total (N = 3179)	T1 <i>(N</i> = 1059)	T2 ( <i>N</i> = 1059)	T3 ( <i>N</i> = 1061)	P-value
		6.79-8.38	8.38-8.98	8.98-12.85	
Age,mean(SD), years	48.8 ± 17.1	43.8 ± 17.4	49.9 ± 17.4	52.8 ± 15.3	< 0.001
Sex, n (%)					< 0.001
Male	1238 (38.9)	344 (32.5)	407 (38.4)	487 (45.9)	
Female	1941 (61.1)	715 (67.5)	652 (61.6)	574 (54.1)	
Race, n (%)					< 0.001
Non-Hispanic White	1432 (45.0)	413 (39)	485 (45.8)	534 (50.3)	
Non-Hispanic Black	660 (20.8)	338 (31.9)	189 (17.8)	133 (12.5)	
Mexican American	488 (15.4)	116 (11)	175 (16.5)	197 (18.6)	
Other Hispanic	337 (10.6)	94 (8.9)	124 (11.7)	119 (11.2)	
Other Race	262 (8.2)	98 (9.3)	86 (8.1)	78 (7.4)	
Marital status, n (%)					0.003
No	1529 (48.1)	554 (52.3)	494 (46.6)	481 (45.3)	
Yes	1650 (51.9)	505 (47.7)	565 (53.4)	580 (54.7)	
PIR, n (%)					0.150
<1.30	1343 (42.2)	432 (40.8)	445 (42.0)	466 (43.9)	
1.31-3.50	1183 (37.2)	384 (36.3)	401 (37.9)	398 (37.5)	
≥3.50	653 (20.5)	243 (22.9)	213 (20.1)	197 (18.6)	
Education level, n (%)					< 0.001
Less than high school	936 (29.4)	264 (24.9)	321 (30.3)	351 (33.1)	
High school or equivalent	785 (24.7)	245 (23.1)	268 (25.3)	272 (25.6)	
Above high school	1458 (45.9)	550 (51.9)	470 (44.4)	438 (41.3)	
Smoking status, n (%)					< 0.001
Never	1510 (47.5)	571 (53.9)	484 (45.7)	455 (42.9)	
Former	740 (23.3)	197 (18.6)	246 (23.2)	297 (28)	
Now	929 (29.2)	291 (27.5)	329 (31.1)	309 (29.1)	
Drinking status, n (%)					< 0.001
Never	412 (13.0)	136 (12.8)	137 (12.9)	139 (13.1)	
Former	592 (18.6)	155 (14.6)	192 (18.1)	245 (23.1)	
Current	2175 (68.4)	768 (72.5)	730 (68.9)	677 (63.8)	

(Continued)

#### TABLE 1 Continued

Variables	Total ( <i>N</i> = 3179)	T1 (N = 1059)	T2 ( <i>N</i> = 1059)	T3 ( <i>N</i> = 1061)	<i>P</i> -value	
		6.79-8.38	8.38-8.98	8.98-12.85		
Drinking status, n (%)					< 0.001	
Hyperlipidemia, n (%)	2362 (74.3)	510 (48.2)	817 (77.1)	1035 (97.5)	< 0.001	
TyG, Mean (SD)	8.7 ± 0.7	8.0 ± 0.3	8.7 ± 0.2	9.5 ± 0.5	< 0.001	
TYG-BMI, Mean (SD)	266.6 ± 75.7	224.0 ± 64.0	267.0 ± 67.1	308.7 ± 70.8	< 0.001	
TYG-WC, Mean (SD)	893.7 ± 191.3	755.1 ± 150.3	890.5 ± 147.3	1035.4 ± 162.0	< 0.001	
TyG-WHtR, Mean (SD)	5.4 ± 1.2	4.6 ± 0.9	5.4 ± 0.9	$6.2 \pm 1.0$	< 0.001	

PIR, poverty-income ratio; TyG, triglyceride-glucose; TyG-BMI, TyG with body mass index; TyG-WC,TyG with waist circumference; TyG-WHtR, TyG with waist-to-height ratio; Other Race, Including Multi-Racial; SD, standard deviation.

## 3.2 Association between TyG-related indices and all-cause mortality

After adjusting for potential confounding factors, a significant curvilinear association was observed between the TyG index, its related indices, and all-cause mortality risk (P < 0.05), as shown in Table 2 (Model 3). Using the T2 group as the reference, the fully adjusted model revealed that the TyG index was significantly associated with mortality risk: the hazard ratio (HR) was 1.34

(95% CI: 1.01–1.79, P = 0.041) for the T1 group and 1.33 (95% CI: 1.03–1.72, P = 0.030) for the T3 group.

The TyG-WC index demonstrated a more pronounced doseresponse relationship. In the fully adjusted model, the T1 group had the highest mortality risk (HR: 1.60, 95% CI: 1.21–2.11, P = 0.001), while the T3 group also showed a significantly elevated risk compared to the reference group (HR: 1.37, 95% CI: 1.07–1.76, P = 0.014).

For both the TyG-BMI and TyG-WHtR indices, a significantly increased risk of all-cause mortality was observed in the T1 groups.

TABLE 2 The association of TyG, TyG-BMI, TyG-WC and TyG-WHtR with All-cause mortality in depression participants.

Variable	Model 1		Model 2		Model 3	
	HR(95%CI)	<i>P</i> -value	HR(95%CI)	<i>P</i> -value	HR(95%CI)	<i>P</i> -value
TyG						
T1	1.37 (1.04~1.80)	0.026	1.30 (0.98~1.73)	0.065	1.34 (1.01~1.79)	0.041
T2	1(Ref)		1(Ref)		1(Ref)	
Т3	1.35 (1.06~1.72)	0.017	1.27 (0.99~1.63)	0.057	1.33 (1.03~1.72)	0.030
TYG-BMI						
T1	1.51 (1.18~1.93)	0.001	1.46 (1.13~1.87)	0.003	1.35 (1.05~1.74)	0.021
T2	1(Ref)		1(Ref)		1(Ref)	
Т3	1.21 (0.93~1.57)	0.162	1.12 (0.86~1.46)	0.398	1.13 (0.87~1.47)	0.367
TYG-WC						
T1	1.69 (1.29~2.22)	<0.001	1.67 (1.27~2.19)	<0.001	1.60 (1.21~2.11)	0.001
T2	1(Ref)		1(Ref)		1(Ref)	
Т3	1.42 (1.11~1.82)	0.006	1.34 (1.05~1.72)	0.020	1.37 (1.07~1.76)	0.014
TyG-WHtR						
T1	1.45 (1.11~1.89)	0.006	1.36 (1.04~1.78)	0.024	1.30 (0.99~1.71)	0.056
T2	1(Ref)		1(Ref)		1(Ref)	
T3	1.23 (0.96~1.57)	0.108	1.15 (0.89~1.47)	0.282	1.16 (0.9~1.49)	0.253

TyG, triglyceride-glucose; TyG-BMI, TyG with body mass index; TyG-WC, TyG with waist circumference; TyG-WHtR, TyG with waist-to-height ratio; PIR, poverty-income ratio; HR, hazard ratio.

Model 1: Adjusted for age, sex.

Model 2:Adjusted for Model 1 + race, marital status, PIR, education level.

Model 3: Adjusted for Model2 + smoking status, drinking status, hyperlipidemia.

Specifically, for the TyG-BMI index, the HR was 1.35 (95% CI: 1.05–1.74, P = 0.021) in the fully adjusted model. Similarly, for the TyG-WHtR index, the T1 group showed a significantly elevated risk in Model 1 (HR: 1.45, 95% CI: 1.11–1.89, P = 0.006) (Table 2).

# 3.3 Curve fitting and inflection point analysis of TyG-related indices and all-cause mortality

After adjusting for potential confounders, we observed U-shaped nonlinear associations between the TyG index and its derivative indices (TyG-BMI, TyG-WC, and TyG-WHtR) and the risk of all-cause mortality (*P* for nonlinearity < 0.05 for all) (Figure 2). For the TyG index, inflection point analysis identified a threshold at 8.443. Below this value, each unit increase in TyG was associated with a 59% reduction in mortality risk (HR: 0.409, 95% CI: 0.205–0.817), whereas each unit increase above 8.443 corresponded to a 34% increase in risk (HR: 1.336, 95% CI: 1.039–1.717). Significant threshold effects were also identified for the derivative indices: TyG-BMI (inflection point: 240.848), TyG-WC (835.303), and TyG-WHtR (5.828). The risk patterns showed statistically significant differences before and after each threshold (likelihood ratio test, P < 0.01). These nonlinear relationships were further validated through segmented regression modeling (Table 3).



#### FIGURE 2

Association between TyG and TyG related Indices with All-Cause Mortality risk in depression participants. TyG,triglyceride-glucose;TyG-BMI,TyG with body mass index;TyG-WC,TyG with waist circumference;TyG-WHtR, TyG with waist-to-height ratio,PIR,poverty-income ratio. Restricted cubic spline curve for the association of TyG-related indices with all-cause mortality. All-cause mortality for (A) TyG index, (B) TyG-BMI index, (C) TyG-WC index and (D) TyG-WHtR index. The solid red lines indicate hazard ratios (HRs), with the width of the red shaded areas representing the 95% confidence intervals (95% Cls). The light blue dashed line serves as the reference line, The intersection point of the reference line is the median by default. The light blue shaded bar areas in the background illustrate the population distribution of TyG-related indices. Adjusted for age, sex, race, marital status, PIR, education level, smoking status, drinking status, hyperlipidemia.

TABLE 3	Threshold effect analysis of the relationship of TyG, TyG-BMI,	
TyG-WC	and TyG-WHtR with All-cause mortality in	
depressio	on participants.	

Breakpoint	HR (95%CI)	P -value				
ТуG						
<8.443	0.409 (0.205,0.817)	0.0113				
≥8.443	1.336 (1.039,1.717)	0.0237				
Likelihood Ratio test	- 0.0040					
TyG-BMI						
<240.848	0.9904 (0.9845,0.9963)	0.0014				
≥240.848	1.0024 (0.9996,1.0051)	0.0946				
Likelihood Ratio test	_	<0.001				
TyG-WC						
<835.303	0.9974 (0.9951,0.9997)	0.0239				
≥835.303	1.0008 (0.9998,1.0018)	0.1347				
Likelihood Ratio test	_	0.0020				
TyG-WHtR						
<5.828	0.1035					
≥5.828	1.352 (1.021,1.791)	0.0353				
Likelihood Ratio test	-	0.0040				

TyG, triglyceride-glucose; TyG-BMI, TyG with body mass index; TyG-WC, TyG with waist circumference; TyG-WHtR, TyG with waist-to-height ratio, PIR, poverty-income ratio. Adjusted for age, sex, race, marital status, PIR, education level, smoking status, drinking status, and hyperlipidemia. HR, hazard ratio.

## 3.4 Subgroup analyses of TyG-related indices and all-cause mortality

Subgroup analyses were performed to assess whether the associations between TyG,TyG-related indices and allcause mortality varied across demographic or clinical subgroups. No significant interaction effects were detected for any of the three indices, indicating that the observed associations were consistent across subgroups. These findings confirm the robustness of the results. Subgroup analysis results are presented in Figure 3.

## 3.5 Kaplan–Meier survival curves of TyGrelated indices and all-cause mortality

Kaplan–Meier survival analyses demonstrated that TyG and its related indices were significantly associated with all-cause mortality in patients with depression (P < 0.001; Supplementary Figure S1). Participants in the T3 group had a markedly lower survival rate compared to those in the T1 group, indicating that higher levels of TyG and TyG-related indices are associated with increased mortality risk.

## 3.6 Sensitivity analysis

Sensitivity analyses were conducted to further validate the robustness of the findings. First, extreme values were trimmed by retaining data within the 0.5%–99.5% percentiles. Second, participants with diabetes were excluded from the analysis. The results remained consistent across both approaches, thereby reinforcing the stability and reliability of the primary associations (Supplementary Tables S1, S2).

## 4 Discussion

Our study yields four key findings. First, the TyG index and TyG-related indices demonstrated a strong association with allcause mortality in individuals with depression. This association remained significant after adjusting for covariates and showed no interaction effects across age, sex, or hyperlipidemia subgroups. Second, the relationship between TyG indices and mortality exhibited a U-shaped nonlinear pattern with clear threshold effects. Third, Kaplan–Meier survival curves confirmed that higher TyG and TyG-related indices were associated with increased all-cause mortality risk. Fourth, these associations remained robust in sensitivity analyses, including the exclusion of outliers and diabetic participants, thereby reinforcing the reliability of our conclusions.

Although the TyG index has been linked to all-cause mortality across various disease states, limited research has explored its role in predicting mortality among individuals with depression. Most existing studies focus on the association between TyG and depressive symptoms, typically within cross-sectional designs that preclude causal inference (33–35). In contrast, our study leveraged a large, population-based cohort (2005–2018) and employed a longitudinal approach. Prior to conducting Cox regression analyses, we rigorously tested the proportional hazards assumption and adjusted for multiple covariates. The results provide compelling evidence of a significant association between TyG levels and mortality risk in depressed populations, addressing a notable gap in the literature.

The observed U-shaped association between TyG indices and all-cause mortality may reflect dual pathophysiological mechanisms (11). At lower TyG levels (T1), impaired energy homeostasis (36) and neuroendocrine dysregulation may worsen depressive symptoms and increase metabolic vulnerability. In contrast, higher TyG levels (T3) likely represent advanced IR (12), systemic inflammation, and cardiometabolic comorbidities—wellestablished contributors to increased mortality in mood disorders (5). Notably, the TyG-WC index exhibited the most pronounced Ushaped curve, suggesting that central adiposity may intensify both ends of this metabolic paradox (11, 37). From a clinical perspective, these findings highlight the need for individualized glycemic monitoring thresholds in patients with depression, moving beyond simplistic linear risk models (11). Therapeutic strategies should aim to balance metabolic regulation with adequate



#### FIGURE 3

Subgroup analyses of TyG-related indices and all-cause mortality. TyG, triglyceride-glucose; TyG-BMI, TyG with body mass index; TyG-WC, TyG with waist circumference; TyG-WHtR, TyG with waist-to-height ratio, PIR, poverty-income ratio. HR, hazard ratio. Forest plots showing the association of TyG and TyG-related indices with the risk of all-cause mortality in depressed individuals. All-cause mortality for **(A)** TyG index, **(B)** TyG-BMI index, **(C)** TyG-WC index and **(D)** TyG-WHtR index. Adjusted for age, sex, race, marital status, PIR, education level, smoking status, drinking status, hyperlipidemia. Purple diamonds indicate point estimates of effect sizes.

nutritional support, particularly given depression's complex relationship with both hyperphagia and appetite loss (5, 38).

The association between TyG-related indices and mortality risk may be mediated by multiple physiological mechanisms (39). First, the notably high risk observed for TyG-WC in the nonhyperlipidemia subgroup (HR: 2.28) suggests that visceral fat accumulation may directly impair vascular endothelial function through the release of free fatty acids (40). This effect may be further exacerbated by the chronic inflammatory state commonly seen in depression, characterized by elevated levels of inflammatory cytokines such as IL-6 and TNF- $\alpha$ , which contribute to oxidative stress (41, 42). Second, threshold effect analysis revealed a protective association below the TyG index inflection point of 8.443 (HR: 0.409), possibly reflecting the role of moderate insulin sensitivity in maintaining metabolic homeostasis (43, 44). In contrast, values above this threshold may contribute to the accumulation of

glucolipotoxicity, resulting in mitochondrial dysfunction and the formation of advanced glycation end-products (AGEs), both of which are implicated in increased mortality risk (41, 45).

Although the inflection point for TyG-WC (835.303) did not reach statistical significance (P = 0.1347), the consistently elevated risk in the T1 group of the segmented model (HR: 1.58, P = 0.001) supports the "visceral fat–inflammation axis" theory (46). This theory posits that pro-inflammatory factors secreted by visceral adipose tissue may act synergistically with IR to accelerate the development of atherosclerosis (47).

This study defined depression using a validated computational approach widely adopted in NHANES and prior research, rather than formal clinical diagnostic criteria. Specifically, the Patient Health Questionnaire-9 (PHQ-9) was used as a screening tool. While the PHQ-9 is a widely used and validated instrument with acceptable sensitivity and specificity for identifying depressive symptoms in both primary care and research settings, it is not a substitute for a comprehensive clinical diagnosis. Clinical diagnosis typically requires an in-depth interview, assessment of symptom duration and functional impairment, and exclusion of alternative medical or psychiatric conditions, elements that the PHQ-9 may not fully capture. Several additional limitations warrant consideration. First, the absence of hormonal data required the use of chronological age to define menopausal status, which limits the precision of our interpretations regarding associations between TyG/TyG-related indices and all-cause mortality in the depressed cohort. Second, the relatively advanced age of many participants presents a limitation, as causes of death (e.g., suicide vs. cardiovascular events) likely vary substantially across age groups. Third, although we performed comprehensive multivariate adjustments for demographic, metabolic, and lifestyle factors, the possibility of residual confounding cannot be ruled out. Additionally, while the exclusion of participants with incomplete data may have introduced selection bias, multiple sensitivity analyses supported the robustness of our primary findings. To improve precision in future studies, we recommend incorporating standardized clinical assessments for participant inclusion.

The findings of this study offer novel evidence linking IR to mortality risk in individuals with depression, supporting the rationale for IR-targeted interventions in the clinical management of this population. Furthermore, we demonstrated a U-shaped association between the TyG index and all-cause mortality, with both low and high TyG values associated with increased mortality risk. These findings support the development of threshold-based, stratified interventions, enabling clinicians to tailor therapeutic strategies according to individual TyG index profiles. Overall, the evidence presented here contributes to advancing precision medicine approaches for managing metabolic–psychiatric comorbidities.

## 5 Conclusion

The TyG index and its related indices are significantly associated with all-cause mortality in patients with depression, with evidence of threshold effects. Based on these findings, it is recommended that TyG-BMI and TyG-WC be incorporated into routine clinical risk assessments for individuals with depression. Early interventions such as lifestyle modifications or targeted anti-inflammatory treatments—may be especially beneficial for individuals without hyperlipidemia. Furthermore, the development of multidimensional risk prediction models that integrate metabolic, psychological, and social factors may advance precision medicine in the management of depression–metabolic comorbidities.

## Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

## **Ethics statement**

Ethics approval was obtained from the NCHS Ethics Review Committee, and participants provided written informed consent. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

## Author contributions

XW: Software, Writing – original draft, Writing – review & editing, Investigation, Methodology, Data curation, Conceptualization. CF: Writing – review & editing. BZ: Writing – review & editing. GJ: Writing – review & editing.

## Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

## Acknowledgments

The authors thank NHANES for data access and Dr. Huanxian Liu (Chinese PLA General Hospital) for technical support.

## **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

## Correction note

This article has been corrected with minor changes. These changes do not impact the scientific content of the article.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations,

## References

1. Dwyer JB, Aftab A, Radhakrishnan R, Widge A, Rodriguez CI, Carpenter LL, et al. Hormonal treatments for major depressive disorder: state of the art. *Am J Psychiatry.* (2020) 177:686–705. doi: 10.1176/appi.ajp.2020.19080848

2. Simon GE, Moise N, Mohr DC. Management of depression in adults: A review. JAMA. (2024) 332:141. doi: 10.1001/jama.2024.5756

3. Repova K, Aziriova S, Krajcirovicova K, Simko F. Cardiovascular therapeutics: A new potential for anxiety treatment? *Med Res Rev.* (2022) 42:1202–45. doi: 10.1002/med.21875

4. Goldfarb M, De Hert M, Detraux J, Di Palo K, Munir H, Music S, et al. Severe mental illness and cardiovascular disease. *J Am Coll Cardiol.* (2022) 80:918–33. doi: 10.1016/j.jacc.2022.06.017

5. Zhang Z, Jackson SL, Gillespie C, Merritt R, Yang Q. Depressive symptoms and mortality among US adults. *JAMA Netw Open.* (2023) 6:e2337011. doi: 10.1001/jamanetworkopen.2023.37011

6. Khan AW, Jandeleit-Dahm KAM. Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches. *Nat Rev Cardiol.* (2025) 22:482–96. doi: 10.1038/s41569-024-01115-w

7. Zhang L, Wang L, Yu M, Wu R, Steffens DC, Potter GG, et al. Hybrid representation learning for cognitive diagnosis in late-life depression over 5 years with structural MRI. *Med Image Anal.* (2024) 94:103135. doi: 10.1016/j.media.2024.103135

8. Younossi ZM, Corey KE, Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. *Gastroenterology*. (2021) 160:912–8. doi: 10.1053/j.gastro.2020.11.051

9. Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected — obesity, impaired metabolic health and COVID-19. *Nat Rev Endocrinol.* (2021) 17:135–49. doi: 10.1038/s41574-020-00462-1

10. Abushamat LA, Shah PA, Eckel RH, Harrison SA, Barb D. The emerging role of glucagon-like peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis. *Clin Gastroenterol Hepatol.* (2024) 22:1565–74. doi: 10.1016/j.cgh.2024.01.032

11. Chen Y, Zhong Z, Gue Y, Banach M, McDowell G, Mikhailidis DP, et al. Impact of surrogates for insulin resistance on mortality and life expectancy in primary care: a nationwide cross-sectional study with registry linkage (LIPIDOGRAM2015). *Lancet Reg Health Eur.* (2025) 49:101182. doi: 10.1016/j.lanepe.2024.101182

12. Lopez-Jaramillo P, Gomez-Arbelaez D, Martinez-Bello D, Abat MEM, Alhabib KF, Avezum Á, et al. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. *Lancet Healthy Longev.* (2023) 4: e23–33. doi: 10.1016/S2666-7568(22)00247-1

13. Beyene HB, Giles C, Huynh K, Wang T, Cinel M, Mellett NA, et al. Metabolic phenotyping of BMI to characterize cardiometabolic risk: evidence from large population-based cohorts. *Nat Commun.* (2023) 14:6280. doi: 10.1038/s41467-023-41963-7

14. Petersen MC, Smith GI, Palacios HH, Farabi SS, Yoshino M, Yoshino J, et al. Cardiometabolic characteristics of people with metabolically healthy and unhealthy obesity. *Cell Metab.* (2024) 36:745–761.e5. doi: 10.1016/j.cmet.2024.03.002

15. West HW, Siddique M, Williams MC, Volpe L, Desai R, Lyasheva M, et al. Deeplearning for epicardial adipose tissue assessment with computed tomography: implications for cardiovascular risk prediction. *JACC Cardiovasc Imaging*. (2023) 16:800–16. doi: 10.1016/j.jcmg.2022.11.018

16. Dang K, Wang X, Hu J, Zhang Y, Cheng L, Qi X, et al. The association between triglyceride-glucose index and its combination with obesity indicators and cardiovascular disease: NHANES 2003-2018. *Cardiovasc Diabetol.* (2024) 23:8. doi: 10.1186/s12933-023-02115-9

17. Zipf G, Chiappa M, Porter KS, Ostchega Y, Lewis BG, Dostal J. National health and nutrition examination survey: plan and operations, 1999-2010. In: *Vital Health Stat Ser 1 Programs Collect Proced* (2013) (56):1–37.

or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2025. 1614421/full#supplementary-material

18. Mao Y, Li X, Li Y, Zhu S, Han X, Zhao R, et al. Association of serum 25hydroxyvitamin d concentrations with all-cause and cause-specific mortality among individuals with depression: A cohort study. *J Affect Disord.* (2024) 352:10–8. doi: 10.1016/j.jad.2024.02.018

19. Li S, An L, Fu Z, Zhang W, Liu H. Association between triglyceride-glucose related indices and all-cause and cause-specific mortality in the general population: a cohort study. *Cardiovasc Diabetol.* (2024) 23:286. doi: 10.1186/s12933-024-02390-0

20. Tang X, Zhang K, He R. The association of triglyceride-glucose and triglycerideglucose related indices with the risk of heart disease in a national. *Cardiovasc Diabetol.* (2025) 24:54. doi: 10.1186/s12933-025-02621-y

21. Brämer GR. International statistical classification of diseases and related health problems. Tenth revision. In: *World Health Stat Q Rapp Trimest Stat Sanit Mond*, vol. 41 Geneva, Switzerland: World Health Statistics Quarterly (ISSN 0379-8070). . (1988). p. 32–6.

22. Liu H, Zhang S, Gong Z, Zhao W, Lin X, Liu Y, et al. Association between migraine and cardiovascular disease mortality: A prospective population-based cohort study. *Headache J Head Face Pain.* (2023) 63:1109–18. doi: 10.1111/head.14616

23. Manea L, Gilbody S, McMillan D. A diagnostic meta-analysis of the Patient Health Questionnaire-9 (PHQ-9) algorithm scoring method as a screen for depression. *Gen Hosp Psychiatry.* (2015) 37:67–75. doi: 10.1016/j.genhosppsych.2014.09.009

24. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Intern Med. (2001) 16:606–13. doi: 10.1046/j.1525-1497.2001.016009606.x

25. Cancino RS, Culpepper L, Sadikova E, Martin J, Jack BW, Mitchell SE. Doseresponse relationship between depressive symptoms and hospital readmission. *J Hosp Med.* (2014) 9:358–64. doi: 10.1002/jhm.2180

26. Mao Y, Li X, Zhu S, Geng Y. Association between dietary fiber intake and risk of depression in patients with or without type 2 diabetes. *Front Neurosci.* (2022) 16:920845. doi: 10.3389/fnins.2022.920845

27. Tang H, Zhang X, Luo N, Huang J, Zhu Y. Association of dietary live microbes and nondietary prebiotic/probiotic intake with cognitive function in older adults: evidence from NHANES. J Gerontol A Biol Sci Med Sci. (2024) 79:glad175. doi: 10.1093/gerona/glad175

28. Rattan P, Penrice DD, Ahn JC, Ferrer A, Patnaik M, Shah VH, et al. Inverse association of telomere length with liver disease and mortality in the US population. *Hepatol Commun.* (2022) 6:399–410. doi: 10.1002/hep4.1803

29. Expert Panel On Detection, Evaluation, And Treatment Of High Blood Cholesterol In Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). *JAMA J Am Med Assoc.* (2001) 285:2486–97. doi: 10.1001/jama.285.19.2486

30. Sutherland C, Hare D, Johnson PJ, Linden DW, Montgomery RA, Droge E. Practical advice on variable selection and reporting using Akaike information criterion. *Proc Biol Sci.* (2023) 290:20231261. doi: 10.1098/rspb.2023.1261

31. Guo M, Wu Y, Gross AL, Karvonen-Gutierrez C, Kobayashi LC. Age at menopause and cognitive function and decline among middle-aged and older women in the China Health and Retirement Longitudinal Study, 2011-2018. *Alzheimers Dement J Alzheimers Assoc.* (2025) 21:e14580. doi: 10.1002/alz.14580

32. Crandall CJ, Mehta JM, Manson JE. Management of menopausal symptoms: A review. JAMA. (2023) 329:405-20. doi: 10.1001/jama.2022.24140

33. Zhang X, Zhao D, Guo S, Yang J, Liu Y. Association between triglyceride glucose index and depression in hypertensive population. *J Clin Hypertens Greenwich Conn.* (2024) 26:177–86. doi: 10.1111/jch.14767

34. Shi P, Fang J, Lou C. Association between triglyceride-glucose (TyG) index and the incidence of depression in US adults with diabetes or pre-diabetes. *Psychiatry Res.* (2025) 344:116328. doi: 10.1016/j.psychres.2024.116328

35. Yy SRZ, Jj C, Sz Q. The association between triglyceride glucose index and depression: data from NHANES 2005-2018. *BMC Psychiatry*. (2021) 21:267. doi: 10.1186/s12888-021-03275-2

36. La Merrill MA, Smith MT, McHale CM, Heindel JJ, Atlas E, Cave MC, et al. Consensus on the key characteristics of metabolism disruptors. *Nat Rev Endocrinol.* (2025) 21:245–61. doi: 10.1038/s41574-024-01059-8

37. Hendryx M, Manson JE, Ostfeld RJ, Chlebowski RT, LeBlanc ES, Waring ME, et al. Intentional weight loss, waist circumference reduction, and mortality risk among postmenopausal women. *JAMA Netw Open.* (2025) 8:e250609. doi: 10.1001/jamanetworkopen.2025.0609

38. Chen L, Tan KM-L, Xu J, Mishra P, Mir SA, Gong M, et al. Exploring multiomics and clinical characteristics linked to accelerated biological aging in Asian women of reproductive age: insights from the S-PRESTO study. *Genome Med.* (2024) 16:128. doi: 10.1186/s13073-024-01403-7

39. Piché M-E, Clavel M-A, Auclair A, Rodríguez-Flores M, O'Connor K, Garceau P, et al. Early benefits of bariatric surgery on subclinical cardiac function: Contribution of visceral fat mobilization. *Metabolism*. (2021) 119:154773. doi: 10.1016/j.metabol.2021.154773

40. Citrin KM, Chaube B, Fernández-Hernando C, Suárez Y. Intracellular endothelial cell metabolism in vascular function and dysfunction. *Trends Endocrinol Metab TEM*. (2024). doi: 10.1016/j.tem.2024.11.004

41. Hong H, Xu Y, Xu J, Zhang J, Xi Y, Pi H, et al. Cadmium exposure impairs pancreatic  $\beta$ -cell function and exaggerates diabetes by disrupting lipid metabolism. *Environ Int.* (2021) 149:106406. doi: 10.1016/j.envint.2021.106406

42. Li Z, Li Q, Wang L, Li C, Xu M, Duan Y, et al. Targeting mitochondriainflammation circle by renal denervation reduces atheroprone endothelial phenotypes and atherosclerosis. *Redox Biol.* (2021) 47:102156. doi: 10.1016/j.redox.2021.102156

43. Cao X, Xia Y, Liu D, He Y, Mu T, Huo Y, et al. Inhibitory effects of Lentinus edodes mycelia polysaccharide on  $\alpha$ -glucosidase, glycation activity and high glucose-induced cell damage. *Carbohydr Polym.* (2020) 246:116659. doi: 10.1016/j.carbpol.2020.116659

44. Sun L, Leng R, Liu M, Su M, He Q, Zhang Z, et al. Endothelial MICU1 protects against vascular inflammation and atherosclerosis by inhibiting mitochondrial calcium uptake. *J Clin Invest.* (2025) 135:e181928. doi: 10.1172/JCI181928

45. Xie F, Liu B, Qiao W, He J-Z, Cheng J, Wang Z-Y, et al. Smooth muscle NF90 deficiency ameliorates diabetic atherosclerotic calcification in male mice via FBXW7-AGER1-AGEs axis. *Nat Commun.* (2024) 15:4985. doi: 10.1038/s41467-024-49315-9

46. Friedline RH, Noh HL, Suk S, Albusharif M, Dagdeviren S, Saengnipanthkul S, et al. IFNγ-IL12 axis regulates intercellular crosstalk in metabolic dysfunctionassociated steatotic liver disease. *Nat Commun.* (2024) 15:5506. doi: 10.1038/s41467-024-49633-y

47. Pietri P, Stefanadis C. Cardiovascular aging and longevity: JACC state-of-the-art review. J Am Coll Cardiol. (2021) 77:189–204. doi: 10.1016/j.jacc.2020.11.023